1. Home
  2. SGMO
  3. SGMO News

Latest Sangamo Therapeutics Inc. (SGMO) News on February 23, 2025

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
SGMO

Business Wire

17 days ago

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025
SGMO

Insider Monkey

2 months ago

Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025

Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
SGMO

Zacks

2 months ago

Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More

Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment Partnership
SGMO

Barrons.com

2 months ago

Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment Partnership

SGMO

MT Newswires

2 months ago

Top Midday Decliners

Sangamo Therapeutics Stock Slumps After Pfizer Terminates Hemophilia A Gene Therapy Partnership
SGMO

MT Newswires

2 months ago

Sangamo Therapeutics Stock Slumps After Pfizer Terminates Hemophilia A Gene Therapy Partnership

SGMO

MT Newswires

2 months ago

Jefferies Cuts Price Target on Sangamo Therapeutics to $3 From $7, Keeps Buy Rating; Shares Fall

SGMO

MT Newswires

2 months ago

Top Midday Stories: Sangamo Shares Fall After Pfizer Exits Collaboration; Dave Denies DOJ Allegations

Pfizer Exit Sends Sangamo Plummeting 50%, Casting Doubt on Hemophilia Gene Therapy's Future
SGMO

GuruFocus.com

2 months ago

Pfizer Exit Sends Sangamo Plummeting 50%, Casting Doubt on Hemophilia Gene Therapy's Future

Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact
SGMO

Investopedia

2 months ago

Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact

SGMO Pre-Market Shares Drop 40% Over Pfizer (PFE) Deal Collapse
SGMO

Insider Monkey

2 months ago

SGMO Pre-Market Shares Drop 40% Over Pfizer (PFE) Deal Collapse

Sangamo stock plummets 50% after Pfizer ends gene therapy deal
SGMO

Yahoo Finance Video

2 months ago

Sangamo stock plummets 50% after Pfizer ends gene therapy deal

Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
SGMO

Benzinga

2 months ago

Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact

SGMO

MT Newswires

2 months ago

Sangamo's Cash on Balance Sheet Seen as 'Overhang' as Pfizer Pulls Out of Hemophilia A Therapy Study, Truist Says

SGMO

MT Newswires

2 months ago

Sector Update: Health Care

Sangamo’s stock sinks 50% as Pfizer halts haemophilia A gene therapy partnership
SGMO

Pharmaceutical Technology

2 months ago

Sangamo’s stock sinks 50% as Pfizer halts haemophilia A gene therapy partnership

SGMO

Investing.com

2 months ago

Sangamo stock crashes 50% after Pfizer terminates HemoA gene therapy deal

SGMO Stock Crashes as Pfizer Ends Deal for Hemophilia Candidate
SGMO

Zacks

2 months ago

SGMO Stock Crashes as Pfizer Ends Deal for Hemophilia Candidate

SGMO

MT Newswires

2 months ago

Wells Fargo Adjusts Price Target on Sangamo Therapeutics to $2 From $3, Keeps Equalweight Rating

Astellas and Sangamo sign capsid deal for neurological diseases
SGMO

Pharmaceutical Technology

2 months ago

Astellas and Sangamo sign capsid deal for neurological diseases

SGMO

MT Newswires

2 months ago

Update: Sangamo Grants Capsid License to Astellas for Neurological Disease Targets; Shares Up Pre-Bell

SGMO

MT Newswires

2 months ago

Sangamo Grants Capsid License to Astellas for Neurological Disease Targets

Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
SGMO

Business Wire

2 months ago

Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
SGMO

PR Newswire

2 months ago

Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

SGMO

MT Newswires

2 months ago

Truist Upgrades Sangamo Therapeutics to Buy From Hold, Reinstates Price Target at $7

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
SGMO

Business Wire

3 months ago

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain

Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations
SGMO

Simply Wall St.

3 months ago

Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations

SGMO

Thomson Reuters StreetEvents

3 months ago

Q3 2024 Sangamo Therapeutics Inc Earnings Call

Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
SGMO

GuruFocus.com

3 months ago

Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates
SGMO

Zacks

3 months ago

Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates

SGMO

Associated Press Finance

3 months ago

Sangamo: Q3 Earnings Snapshot

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
SGMO

Business Wire

3 months ago

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results

Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
SGMO

Business Wire

4 months ago

Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week
SGMO

Simply Wall St.

4 months ago

individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week

Merck acquires cancer drug startup; Elevidys ex-US sales rise
SGMO

BioPharma Dive

4 months ago

Merck acquires cancer drug startup; Elevidys ex-US sales rise

SGMO

MT Newswires

4 months ago

Sangamo Therapeutics Shares Surge After US FDA Clears Potential Fabry Disease Treatment for Expedited Review

Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025
SGMO

Business Wire

4 months ago

Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025

Investors in Sangamo Therapeutics (NASDAQ:SGMO) from three years ago are still down 90%, even after 13% gain this past week
SGMO

Simply Wall St.

5 months ago

Investors in Sangamo Therapeutics (NASDAQ:SGMO) from three years ago are still down 90%, even after 13% gain this past week

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Just Reported And Analysts Have Been Lifting Their Price Targets
SGMO

Simply Wall St.

6 months ago

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Just Reported And Analysts Have Been Lifting Their Price Targets

SGMO

Thomson Reuters StreetEvents

7 months ago

Q2 2024 Sangamo Therapeutics Inc Earnings Call

Genentech and Sangamo to develop neurodegenerative disease therapies
SGMO

Pharmaceutical Technology

7 months ago

Genentech and Sangamo to develop neurodegenerative disease therapies

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
SGMO

Zacks

7 months ago

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates

SGMO

Associated Press Finance

7 months ago

Sangamo: Q2 Earnings Snapshot

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results
SGMO

Business Wire

7 months ago

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results

Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs
SGMO

BioPharma Dive

7 months ago

Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs

Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases
SGMO

Business Wire

7 months ago

Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases

Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
SGMO

Business Wire

7 months ago

Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast

Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate
SGMO

Business Wire

7 months ago

Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate

Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?
SGMO

Zacks

8 months ago

Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?

We Think Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package Needs To Be Put Under A Microscope
SGMO

Simply Wall St.

9 months ago

We Think Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package Needs To Be Put Under A Microscope

US$3.50 - That's What Analysts Think Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is Worth After These Results
SGMO

Simply Wall St.

9 months ago

US$3.50 - That's What Analysts Think Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is Worth After These Results

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript
SGMO

Insider Monkey

9 months ago

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript

Sangamo Therapeutics First Quarter 2024 Earnings: US$0.27 loss per share (vs US$0.13 profit in 1Q 2023)
SGMO

Simply Wall St.

9 months ago

Sangamo Therapeutics First Quarter 2024 Earnings: US$0.27 loss per share (vs US$0.13 profit in 1Q 2023)

SGMO

GuruFocus.com

9 months ago

Sangamo Therapeutics Reports Q1 2024 Results: A Deep Dive into Financials and Strategic Highlights

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates
SGMO

Zacks

9 months ago

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates

SGMO

Associated Press Finance

9 months ago

Sangamo: Q1 Earnings Snapshot

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
SGMO

Business Wire

9 months ago

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
SGMO

Business Wire

9 months ago

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing

Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
SGMO

Zacks

10 months ago

Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates

Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
SGMO

Business Wire

10 months ago

Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
SGMO

Business Wire

10 months ago

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today
SGMO

Simply Wall St.

a year ago

What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
SGMO

Business Wire

a year ago

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering

Sangamo Therapeutics Full Year 2023 Earnings: Misses Expectations
SGMO

Simply Wall St.

a year ago

Sangamo Therapeutics Full Year 2023 Earnings: Misses Expectations

SGMO

Thomson Reuters StreetEvents

a year ago

Q4 2023 Sangamo Therapeutics Inc Earnings Call

SGMO

Associated Press Finance

a year ago

Sangamo: Q4 Earnings Snapshot

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
SGMO

Business Wire

a year ago

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
SGMO

Business Wire

a year ago

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
SGMO

Business Wire

a year ago

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast

Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
SGMO

Business Wire

a year ago

Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease

With 55% ownership of the shares, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is heavily dominated by institutional owners
SGMO

Simply Wall St.

a year ago

With 55% ownership of the shares, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is heavily dominated by institutional owners

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
SGMO

Business Wire

a year ago

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile

Seanergy Maritime Achieves Key Partnership with European Union Funding and Major Industry Stakeholders Under SAFeCRAFT to Revolutionize Maritime Propulsion for Existing Vessels
SGMO

GlobeNewswire

a year ago

Seanergy Maritime Achieves Key Partnership with European Union Funding and Major Industry Stakeholders Under SAFeCRAFT to Revolutionize Maritime Propulsion for Existing Vessels

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SGMO

GlobeNewswire

a year ago

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback
SGMO

Zacks

a year ago

Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback

Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why
SGMO

Zacks

a year ago

Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why

Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study
SGMO

Zacks

a year ago

Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
SGMO

GlobeNewswire

a year ago

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Eltek (NASDAQ:ELTK) Is Very Good At Capital Allocation
SGMO

Simply Wall St.

a year ago

Eltek (NASDAQ:ELTK) Is Very Good At Capital Allocation

Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH
SGMO

Business Wire

a year ago

Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH

Individual investors in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) are its biggest bettors, and their bets paid off as stock gained 20% last week
SGMO

Simply Wall St.

a year ago

Individual investors in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) are its biggest bettors, and their bets paid off as stock gained 20% last week

Crunch Fitness, Appian, Pinstripes CEOs and more: C-Suite Insights
SGMO

Yahoo Finance Video

a year ago

Crunch Fitness, Appian, Pinstripes CEOs and more: C-Suite Insights

Spruce Biosciences Provides Clinical Program Updates and Outlook for 2024
SGMO

Business Wire

a year ago

Spruce Biosciences Provides Clinical Program Updates and Outlook for 2024

Pinstripes looking to expand internationally, CEO explains
SGMO

Yahoo Finance Video

a year ago

Pinstripes looking to expand internationally, CEO explains

Does Brainsway Ltd. Sponsored ADR (BWAY) Have the Potential to Rally 48.15% as Wall Street Analysts Expect?
SGMO

Zacks

a year ago

Does Brainsway Ltd. Sponsored ADR (BWAY) Have the Potential to Rally 48.15% as Wall Street Analysts Expect?

SGMO

Business Wire

a year ago

Bragg Gaming Supplies Online Casino Game Aggregation for Superbet in Brazil

How Much Upside is Left in 908 Devices Inc. (MASS)? Wall Street Analysts Think 100.39%
SGMO

Zacks

a year ago

How Much Upside is Left in 908 Devices Inc. (MASS)? Wall Street Analysts Think 100.39%

7 Dividend Stocks I Wouldn’t Touch With a 10-Foot Pole
SGMO

InvestorPlace

a year ago

7 Dividend Stocks I Wouldn’t Touch With a 10-Foot Pole

3 Growthy Gaming Stocks Worth Playing in 2024
SGMO

InvestorPlace

a year ago

3 Growthy Gaming Stocks Worth Playing in 2024

Frequency Electronics, Inc.'s (NASDAQ:FEIM) Stock Is Going Strong: Have Financials A Role To Play?
SGMO

Simply Wall St.

a year ago

Frequency Electronics, Inc.'s (NASDAQ:FEIM) Stock Is Going Strong: Have Financials A Role To Play?

What Makes Corvus (CRVS) a New Buy Stock
SGMO

Zacks

a year ago

What Makes Corvus (CRVS) a New Buy Stock

SGMO

Business Wire

a year ago

dMY Squared Technology Group, Inc. Announces Postponement of Special Meeting to January 2, 2024 and Extension of Redemption Deadline to December 28, 2023

Syntec Optics Holdings, Inc.'s (NASDAQ:OPTX) top owners are individual investors with 55% stake, while 45% is held by insiders
SGMO

Simply Wall St.

a year ago

Syntec Optics Holdings, Inc.'s (NASDAQ:OPTX) top owners are individual investors with 55% stake, while 45% is held by insiders

U.S. Century Bank Names William Turner New Executive Vice President and Chief Credit Officer
SGMO

GlobeNewswire

a year ago

U.S. Century Bank Names William Turner New Executive Vice President and Chief Credit Officer

Analysts Expect Breakeven For Bragg Gaming Group Inc. (TSE:BRAG) Before Long
SGMO

Simply Wall St.

a year ago

Analysts Expect Breakeven For Bragg Gaming Group Inc. (TSE:BRAG) Before Long

Syntec Optics to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference (Nasdaq: OPTX)
SGMO

GlobeNewswire

a year ago

Syntec Optics to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference (Nasdaq: OPTX)

Shell's (SHEL) Prelude LNG Facility to Restart in December
SGMO

Zacks

a year ago

Shell's (SHEL) Prelude LNG Facility to Restart in December

Returns Are Gaining Momentum At Big 5 Sporting Goods (NASDAQ:BGFV)
SGMO

Simply Wall St.

a year ago

Returns Are Gaining Momentum At Big 5 Sporting Goods (NASDAQ:BGFV)

VIZSLA SILVER REPORTS ADDITIONAL HIGH-GRADE INTERCEPTS ON THE COPALA AND COPALA 2 STRUCTURES
SGMO

CNW Group

a year ago

VIZSLA SILVER REPORTS ADDITIONAL HIGH-GRADE INTERCEPTS ON THE COPALA AND COPALA 2 STRUCTURES

Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky
SGMO

Simply Wall St.

a year ago

Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky

Share on Social Networks: